AR055810A1 - Uso de inhibidores de acetilcolinesterasa e inhibidores de la produccion de beta-app o acumulacion de a-beta - Google Patents
Uso de inhibidores de acetilcolinesterasa e inhibidores de la produccion de beta-app o acumulacion de a-betaInfo
- Publication number
- AR055810A1 AR055810A1 ARP050100547A ARP050100547A AR055810A1 AR 055810 A1 AR055810 A1 AR 055810A1 AR P050100547 A ARP050100547 A AR P050100547A AR P050100547 A ARP050100547 A AR P050100547A AR 055810 A1 AR055810 A1 AR 055810A1
- Authority
- AR
- Argentina
- Prior art keywords
- beta
- inhibitors
- accumulation
- acetilcolinesterase
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Método mejorado para tratar, reducir o retardar desordenes cognitivos asociados con el péptido beta-amiloide, ya sea en combinacion con un tratamiento por terapia de reemplazo colinomimético o como tratamiento profiláctico. Reivindicacion 1: Uso de un inhibidor de acetilcolinesterasa elegido del grupo que comprende (-)-fenserina, donepezil, rivaestigmina, metrifonato, fisoestigmina, eptaestigmina, galantamina, y huperzina A, y un compuesto que inhibe la produccion de beta-APP o inhibe o retarda la acumulacion de Abeta, para la preparacion de un medicamento para el tratamiento de desordenes cognitivos asociados con la acumulacion de Abeta.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54504604P | 2004-02-17 | 2004-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR055810A1 true AR055810A1 (es) | 2007-09-12 |
Family
ID=34837581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050100547A AR055810A1 (es) | 2004-02-17 | 2005-02-16 | Uso de inhibidores de acetilcolinesterasa e inhibidores de la produccion de beta-app o acumulacion de a-beta |
Country Status (10)
Country | Link |
---|---|
US (1) | US20050182044A1 (es) |
EP (1) | EP1576955A1 (es) |
JP (1) | JP2005232171A (es) |
KR (1) | KR20070013265A (es) |
CN (1) | CN1921846A (es) |
AR (1) | AR055810A1 (es) |
AU (1) | AU2005215788A1 (es) |
CA (1) | CA2555084A1 (es) |
IL (1) | IL177449A0 (es) |
WO (1) | WO2005079789A1 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007529545A (ja) | 2004-03-19 | 2007-10-25 | アクソニクス,インコーポレイテッド | ダウン症候群の治療法 |
WO2007097304A1 (ja) | 2006-02-20 | 2007-08-30 | Shiseido Co., Ltd. | 油中水型乳化日焼け止め化粧料 |
JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体 |
JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
ES2533484T3 (es) | 2007-04-18 | 2015-04-10 | Probiodrug Ag | Derivados de tiourea como inhibidores de la glutaminil ciclasa |
ES2332846B1 (es) | 2007-10-26 | 2010-07-08 | Grifols, S.A. | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. |
US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
BG110141A (en) * | 2008-05-23 | 2009-12-31 | "Софарма" Ад | GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE |
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
EA022007B1 (ru) | 2009-09-11 | 2015-10-30 | Пробиодруг Аг | Гетероциклические производные в качестве ингибиторов глутаминилциклазы |
JP6082250B2 (ja) | 2010-02-09 | 2017-02-15 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 認知機能を改善するための方法および組成物 |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
KR101790806B1 (ko) | 2010-03-10 | 2017-11-20 | 프로비오드룩 아게 | 글루타미닐 사이클라제(qc, ec 2.3.2.5)의 헤테로사이클릭 억제제 |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
US20120225922A1 (en) | 2011-03-04 | 2012-09-06 | Qr Pharma | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
CN104869993B (zh) * | 2012-10-25 | 2019-01-15 | 通用医疗公司 | 治疗阿尔茨海默病及相关疾病的组合疗法 |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
KR101472916B1 (ko) | 2013-06-27 | 2014-12-16 | 한국과학기술연구원 | 모르폴린 또는 피페라진 화합물, 및 도네페질을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물 |
AU2014340182B2 (en) | 2013-10-22 | 2019-05-23 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
NZ738682A (en) | 2015-05-22 | 2022-01-28 | Agenebio Inc | Extended release pharmaceutical compositions of levetiracetam |
US10111860B1 (en) | 2016-01-15 | 2018-10-30 | Aristea Translational Medicine Corporation | Compositions and methods for treating concussion |
US10864192B2 (en) | 2016-01-15 | 2020-12-15 | Aristea Translational Medicine Corporation | Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions |
CN116889562A (zh) | 2016-08-31 | 2023-10-17 | 通用医疗公司 | 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞 |
WO2018217892A1 (en) | 2017-05-24 | 2018-11-29 | Qr Pharma, Inc. | Prevention or treatment of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
KR20210071943A (ko) | 2018-07-02 | 2021-06-16 | 더 제너럴 하스피탈 코포레이션 | 크로몰린 소듐 및 α-락토스의 분말화된 제형 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133930A (en) * | 1961-08-15 | 1964-05-19 | Ciba Geigy Corp | Ester and amide derivatives of thieno-[3, 2-b] indole 3-carboxylic acids |
IL72684A (en) * | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
US4791107A (en) * | 1986-07-16 | 1988-12-13 | Hoechst-Roussel Pharmaceuticals, Inc. | Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use |
IT1225462B (it) * | 1987-04-03 | 1990-11-14 | Mediolanum Farmaceutici Srl | Sali organici di derivati della fisostigmina |
US4900748A (en) * | 1988-03-04 | 1990-02-13 | The United States Of America As Represented By The Department Of Health And Human Services | Carbamates related to (-)-physostigmine as cholinergic agents |
DE3843239C1 (es) * | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
US4971992A (en) * | 1989-03-27 | 1990-11-20 | Hoechst-Roussel Pharmaceuticals Inc. | Carbonate derivatives of eseroline |
US4996201A (en) * | 1989-08-02 | 1991-02-26 | Warner-Lambert Co. | 4-(N-substituted amino)-2-butynyl-1-carbamates and thiocarbamates and derivatives thereof as centrally acting muscarinic agents |
US4914102A (en) * | 1989-09-28 | 1990-04-03 | Hoechst Roussel Pharmaceuticals, Inc. | N-aminocarbamates related to physostigmine, pharmacentical compositions and use |
US5077289A (en) * | 1989-11-30 | 1991-12-31 | Hoechst Roussel Pharmaceuticals Inc. | Memory enhancing and analgesic aminocarbonylcarbamates related to physostigmine |
US5171750A (en) * | 1991-09-26 | 1992-12-15 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted phenserines as specific inhibitors of acetylcholinesterase |
ES2201050T3 (es) * | 1991-09-26 | 2004-03-16 | The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services | Compuestos que presentan una inhibicion selectiva de la acteil-colinesterasa. |
US5409948A (en) * | 1992-11-23 | 1995-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating cognitive disorders with phenserine |
TW334423B (en) * | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
US6160018A (en) * | 1995-03-13 | 2000-12-12 | Loma Linda University Medical Center | Prophylactic composition and method for alzheimer's Disease |
US5738723A (en) * | 1995-11-28 | 1998-04-14 | Pilot Industries, Inc. | System for forming metal tubing |
US6153652A (en) * | 1996-11-22 | 2000-11-28 | Elan Pharmaceuticals, Inc. | N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
AU749088C (en) * | 1997-07-09 | 2005-11-03 | Axonyx, Inc. | Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of Alzheimer's disease and dementias |
AU6053900A (en) * | 1999-06-25 | 2001-01-31 | Morris Notelovitz | Compositions for treating or preventing neurodegeneration and cognitive decline |
US20010036949A1 (en) * | 2000-05-09 | 2001-11-01 | Coe Jotham Wadsworth | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
US7153882B2 (en) * | 2000-11-02 | 2006-12-26 | The United States Of America As Represented By The Department Of Health And Human Services | Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof |
US20030138375A1 (en) * | 2001-06-06 | 2003-07-24 | Mcgill University | Individualization of therapy with Alzheimer's disease agents |
AU2003228796A1 (en) * | 2002-05-01 | 2003-11-17 | Eisai Co., Ltd. | Cholinesterase inhibitors to prevent injuries caused by chemicals |
WO2004034963A2 (en) * | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
GB0322140D0 (en) * | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
-
2005
- 2005-02-15 US US11/059,191 patent/US20050182044A1/en not_active Abandoned
- 2005-02-16 CN CNA2005800051549A patent/CN1921846A/zh active Pending
- 2005-02-16 CA CA002555084A patent/CA2555084A1/en not_active Abandoned
- 2005-02-16 WO PCT/US2005/005099 patent/WO2005079789A1/en active Application Filing
- 2005-02-16 KR KR1020067016470A patent/KR20070013265A/ko not_active Application Discontinuation
- 2005-02-16 AU AU2005215788A patent/AU2005215788A1/en not_active Abandoned
- 2005-02-16 AR ARP050100547A patent/AR055810A1/es unknown
- 2005-02-17 JP JP2005041337A patent/JP2005232171A/ja not_active Withdrawn
- 2005-02-17 EP EP05075389A patent/EP1576955A1/en not_active Withdrawn
-
2006
- 2006-08-10 IL IL177449A patent/IL177449A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20070013265A (ko) | 2007-01-30 |
WO2005079789A1 (en) | 2005-09-01 |
JP2005232171A (ja) | 2005-09-02 |
CA2555084A1 (en) | 2005-09-01 |
AU2005215788A1 (en) | 2005-09-01 |
EP1576955A1 (en) | 2005-09-21 |
US20050182044A1 (en) | 2005-08-18 |
IL177449A0 (en) | 2006-12-10 |
CN1921846A (zh) | 2007-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR055810A1 (es) | Uso de inhibidores de acetilcolinesterasa e inhibidores de la produccion de beta-app o acumulacion de a-beta | |
MX2009000285A (es) | Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas. | |
MX2009009761A (es) | Composiciones y estuches para tratamiento de la influenza. | |
JO3002B1 (ar) | مركبات و تركيبات كمثبطات كيناز بروتين | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
PL2134704T3 (pl) | Związki i kompozycje pełniące rolę modulatorów aktywności GPR119 | |
MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
EA200800006A1 (ru) | Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i | |
RS52102B (en) | PIRPHENIDONE THERAPY Avoiding FLUVOXAMINE | |
MX2007004479A (es) | Compuestoss para supresion sin sentido y metodos para su uso. | |
SG10201407403UA (en) | Treatments For Gastrointestinal Disorders | |
WO2009009417A3 (en) | Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion | |
HK1162502A1 (en) | Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3 | |
MX2009005725A (es) | Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13. | |
MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
WO2009105217A3 (en) | Complement inhibitors as therapeutic agents for treatment of cancer | |
MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
TW200509949A (en) | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents | |
IL186707A (en) | Mitotic quinine inhibitors and medical preparations containing them | |
AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
TW200505443A (en) | Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
TW200507840A (en) | Method of treating multiple myeloma | |
TW200719903A (en) | Compositions for the treatment of neoplasms | |
HK1102626A1 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases | |
MX2009008073A (es) | Inhibidores de epoxido hidrolasa solubles para el tratamiento de sindrome metabolico y trastornos relacionados. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |